STOCK TITAN

Pulmonx Corporation - LUNG STOCK NEWS

Welcome to our dedicated page for Pulmonx Corporation news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx Corporation stock.

Pulmonx Corporation (Nasdaq: LUNG) is a leading medical technology company dedicated to transforming the treatment of severe lung diseases. The company's primary focus is on developing life-changing, minimally invasive technologies to enhance the lives of patients suffering from emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). Pulmonx's flagship product, the Zephyr Endobronchial Valve (EBV), offers a non-surgical treatment option to reduce the volume of diseased lung tissue, thereby improving breathing and increasing patients' activity levels. This innovative approach provides a viable alternative to lung volume reduction surgery and lung transplantation, which have significant limitations and risks.

Pulmonx also offers the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which work in tandem with the Zephyr Valve to optimize patient selection and treatment outcomes. These technologies are pivotal in managing advanced emphysema and are commercially available in over 25 countries.

In recent financial updates, Pulmonx reported robust growth, with total worldwide revenue reaching $17.2 million in Q2 2023, marking a 23% increase compared to the same period in 2022. U.S. revenue alone saw a 28% rise, highlighting the strong domestic market traction. The company's ongoing commercial success and adoption of Zephyr Valve procedures are driving this growth.

Pulmonx's fiscal health remains strong, with a gross profit of $12.7 million in Q2 2023 and a gross margin of 74%. Operating expenses rose to $29.2 million, mainly due to increased clinical and development costs associated with the AeriSeal program, alongside higher selling, legal, and stock-based compensation expenses. Despite a net loss of $16.2 million for the quarter, the company maintains significant cash reserves, totaling $147.6 million as of June 30, 2023.

Looking ahead, Pulmonx has raised its 2023 revenue guidance to $64-$66 million, reflecting an expected growth rate of 19%-23% over the previous year. Operating expenses for the year are projected to be between $112 million and $114 million. The company remains committed to expanding its global market reach and meeting the substantial unmet clinical needs of patients with severe emphysema.

For investors and stakeholders, Pulmonx represents a dynamic and promising entity in the medtech space, continually striving to enhance patient outcomes through groundbreaking innovations in pulmonary care.

Rhea-AI Summary

Pulmonx Corporation (NASDAQ: LUNG) announced that Blue Cross Blue Shield of Michigan and Horizon BCBS of New Jersey have issued positive coverage policies for the Zephyr® Endobronchial Valve, a treatment for severe emphysema. This gives access to nearly 10 million covered lives, adding to existing BCBS coverage for 69 million members. The Zephyr Valve is minimally invasive and improves lung function without the risks of major surgery. More than 25,000 patients have been treated with the valve globally, with significant clinical backing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
-
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will engage in fireside chats at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 7:00 AM PT and the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM PT. Interested parties can access live and archived webcasts on the Pulmonx website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr Endobronchial Valve, which has received FDA approval and is available in over 25 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
conferences
-
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) announced that Anthem Blue Cross Blue Shield has issued a positive coverage policy for its Zephyr® Valve, a minimally invasive treatment for severe emphysema, affecting 34 million lives. This adds to existing coverage from other BCBS plans, totaling 59 million covered members in the US. The Zephyr Valve improves lung function, exercise capacity, and quality of life, with over 20,000 patients treated globally. Glen French, CEO of Pulmonx, praised the decision as a significant advancement for patients suffering from severe breathlessness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
Rhea-AI Summary

Pulmonx Corporation (LUNG) reported a 232% increase in Q2 2021 revenue, reaching $12.2 million, due to recovering procedure volumes post-COVID-19. Gross margin improved to 74% from 28% in the prior year. U.S. revenue surged 343% to $6.6 million, while international revenue rose 157% to $5.6 million. Despite increased operating expenses of $21.1 million, the company continues to invest in growth. Pulmonx raised its full-year revenue guidance to $49-$51 million, signaling 50%-56% growth over 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
-
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) has appointed Alissa Hsu Lynch and Tiffany Sullivan to its Board of Directors as of July 29, 2021. Lynch, with over 20 years of experience in MedTech and consumer marketing, currently leads MedTech Strategy and Solutions for Google Cloud. Sullivan serves as COO of Physician Services at New York-Presbyterian Hospital, bringing extensive healthcare delivery experience. Their appointments are expected to enhance Pulmonx's ability to scale its innovative treatments for chronic lung diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
management
-
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 8:30 AM PT / 11:30 AM ET. Interested individuals can access a live and archived webcast on Pulmonx's website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, particularly its Zephyr® Endobronchial Valve, which received FDA pre-market approval as a breakthrough device. The Zephyr Valve is available in over 25 countries and has been used in more than 20,000 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
conferences
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) published long-term follow-up data from the IMPACT Study, showcasing the Zephyr® Valve's effectiveness for patients with severe COPD/emphysema and homogenous disease distribution. The study highlights significant benefits over 12 months, including improved lung function (FEV1), increased quality of life (SGRQ), enhanced exercise capacity (6MWD), and reduced hyperinflation. This minimally invasive treatment is the only FDA-approved option for this patient group, providing much-needed relief where traditional medications fail.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will release its Q2 2021 financial results on August 3, 2021, after the market closes. A conference call for this announcement will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can join by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 5682784. Pulmonx is a leader in minimally invasive treatments for severe lung disease, notably with its Zephyr Endobronchial Valve, used to treat over 20,000 patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
conferences earnings
-
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) presented long-term data from the TRANSFORM study at the ATS 2021 International Conference, highlighting the sustained benefits of the Zephyr® Endobronchial Valve in patients with severe COPD/emphysema. The results indicate significant improvements in lung function, quality of life, and exercise capacity for up to 24 months post-treatment. This minimally invasive procedure, offering a viable alternative to major surgery, has treated over 20,000 patients globally, showcasing its acceptance in clinical guidelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) reported a 7% increase in worldwide revenue to $9.2 million for Q1 2021, with a gross margin improvement to 71.5%. U.S. revenue declined 5% to $4.3 million, while international revenue surged 20% to $5.0 million. Operating expenses rose 59% to $18.6 million, leading to a net loss of $12.0 million or $0.34 per share. The company raised its 2021 revenue outlook to $48-$50 million, representing 47%-53% growth year-over-year, despite ongoing COVID-19 uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags

FAQ

What is the current stock price of Pulmonx Corporation (LUNG)?

The current stock price of Pulmonx Corporation (LUNG) is $6.15 as of December 20, 2024.

What is the market cap of Pulmonx Corporation (LUNG)?

The market cap of Pulmonx Corporation (LUNG) is approximately 236.9M.

What is Pulmonx Corporation's primary focus?

Pulmonx Corporation focuses on developing minimally invasive technologies to improve the lives of patients with severe lung diseases, particularly emphysema.

What products does Pulmonx offer?

Pulmonx offers the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and StratX Lung Analysis Platform, designed to treat and assess patients with severe emphysema.

How does the Zephyr Endobronchial Valve work?

The Zephyr Valve is a tiny, one-way valve that reduces the volume of diseased lung tissue by blocking airflow, thereby improving breathing and activity levels in emphysema patients.

What recent financial achievements has Pulmonx reported?

In Q2 2023, Pulmonx reported total worldwide revenue of $17.2 million, a 23% increase from the same period in 2022, with significant growth in both U.S. and international markets.

What is Pulmonx's financial outlook for 2023?

Pulmonx expects 2023 revenue to range between $64 million and $66 million, with operating expenses projected at $112 million to $114 million.

In which markets are Pulmonx's products commercially available?

Pulmonx's products, including the Zephyr Valve, are commercially available in more than 25 countries globally.

What are the key benefits of the Zephyr Valve treatment?

The Zephyr Valve treatment is a non-surgical, minimally invasive option that can significantly improve breathing and quality of life for patients with severe emphysema.

How does Pulmonx support its products' adoption in the medical community?

Pulmonx supports the adoption of its products through education, training, and ongoing clinical research to demonstrate efficacy and safety.

Who is the current interim CFO of Pulmonx Corporation?

John McKune, Vice President, Corporate Controller, has been appointed as the interim Chief Financial Officer of Pulmonx Corporation, effective immediately.

Where can I find more information about Pulmonx Corporation?

More information about Pulmonx Corporation and its products can be found on their official website at www.Pulmonx.com.

Pulmonx Corporation

Nasdaq:LUNG

LUNG Rankings

LUNG Stock Data

236.93M
37.60M
4.98%
94.91%
2.13%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY